SOD1 and metabolic dysfunction-associated steatotic liver disease: The serum activity of SOD was significantly elevated in patients suffering from early MASLD and advanced MASLD as compared to controls, indicating an adaptive reaction to the increased production of ROS during MASLD (Świderska et al. 2019).